Tablet-Based Brain Testing Platform Validated for Remote Dementia Diagnosis
Italian multicenter trial validates Tenèpsia®, a tablet-based neuropsychological platform, to standardize remote dementia assessment across 250 patients.
Summary
A completed Italian multicenter study enrolled 250 participants to establish normative data and clinically validate Tenèpsia®, a tablet-based teleneuropsychological platform certified as a Class IIa Medical Device. The trial, coordinated through the Italian Neuroscience and Neurorehabilitation Network, aimed to standardize remote cognitive assessment for Mild Neurocognitive Disorder and Alzheimer's disease. Digital cognitive testing offers significant advantages for older adults, especially those with mobility limitations or living in rural and underserved areas. By generating harmonized normative data across multiple sites, the study seeks to make remote neuropsychological evaluation clinically equivalent to in-person testing — a critical step toward scalable, accessible dementia diagnosis and monitoring.
Detailed Summary
Diagnosing and tracking dementia early is one of the most pressing challenges in modern medicine. Neuropsychological assessment sits at the heart of current diagnostic criteria for Mild Neurocognitive Disorder and Alzheimer's disease, yet access to qualified neuropsychologists remains uneven — a gap that telemedicine could help close. This trial asks whether a tablet-based platform can match the rigor of traditional in-person cognitive testing.
The study enrolled 250 participants and was conducted across multiple centers within Italy's National Neuroscience and Neurorehabilitation Network. Researchers aimed to establish normative data for Tenèpsia®, a tablet-based teleneuropsychological platform that holds Class IIa Medical Device certification. The platform was also evaluated for diagnostic performance in patients with confirmed or suspected neurocognitive disorders, supporting both clinical care and future research applications.
While detailed outcome data are not yet published, the study's completion by the end of 2025 positions it as a foundational normative dataset for Italian clinical practice. Harmonizing assessment protocols across sites is critical: without shared normative references, scores from different centers cannot be meaningfully compared, limiting multicenter research and treatment monitoring.
The clinical implications are substantial. Tablet-based assessments could dramatically expand access to cognitive screening for older adults who face transportation barriers, live in rural areas, or have mobility limitations. The COVID-19 pandemic accelerated acceptance of remote healthcare, and validated digital tools now have a realistic path to mainstream adoption in neurology and geriatrics.
Caveats apply. This summary is based on the abstract only; full methodology, outcome measures, and results are not yet publicly available. The normative data will reflect an Italian population, limiting immediate generalizability to other linguistic and cultural groups. Whether Tenèpsia® performance matches gold-standard in-person assessments in sensitivity and specificity remains to be confirmed by the published results.
Key Findings
- Tenèpsia® is a Class IIa Medical Device certified tablet platform designed to standardize remote neuropsychological testing.
- The 250-participant multicenter trial aims to produce harmonized Italian normative data for dementia assessment.
- Tablet-based testing improves access for older adults with mobility limitations or living in underserved areas.
- Harmonized norms across sites are essential for multicenter clinical trials monitoring Alzheimer's disease progression.
- Trial completion is set for late 2025, with full results expected to inform Italian and broader European clinical guidelines.
Methodology
This is a completed multicenter observational and validation study enrolling 250 participants with cognitive impairment, sponsored by IRCCS National Neurological Institute 'C. Mondino' Foundation and conducted within the Italian Neuroscience and Neurorehabilitation Network. The study ran from December 2024 through December 2025. The design focused on normative data collection and diagnostic performance evaluation of the Tenèpsia® tablet platform.
Study Limitations
This summary is based on the abstract only, as full study results are not yet publicly available; methodology, primary outcomes, and statistical findings cannot be fully evaluated. Normative data generated from an Italian cohort may not generalize directly to other languages, cultures, or healthcare systems. Diagnostic sensitivity and specificity relative to gold-standard in-person neuropsychological batteries remain to be published.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: